A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of pyrvinium pamoate for the
treatment of pancreatic ductal adenocarcinoma that cannot be removed by surgery (resectable).
Pyrvinium pamoate may slow down tumor growth and help patients live longer.